Cardiothoracic & vascular anesthesia
High-Flow Nasal Oxygen Therapy After Cardiac Surgery: A Randomized Clinical Trial
Primary result · DAH90 without increased supportResult — go to the resultMedian difference 0 95% CI 0–0Authors' conclusion
In this randomized clinical trial of HFNOT in patients at increased risk of postoperative pulmonary complications after nonemergent cardiac surgery, HFNOT did not improve DAH90 without increased support.
Study context
- Population
- Adults undergoing nonemergent cardiac surgery with a risk factor for pulmonary complications (COPD, asthma, recent lower respiratory tract infection, BMI ≥35, or smoking >10 pack-years); 17 centres in 3 countries1,224 with complete DAH90 data
- Participants
- 1,280 adults
- Comparison
- Prophylactic high-flow nasal oxygen therapy (HFNOT) vs standard oxygen therapy (SOT) for ≥16 h after postoperative extubation
- HFNOTn = 640
- SOTn = 640reference
- Primary endpoint
- DAH without increased support compared with baseline (DAH90)
- Follow-up
- 90 days
Methodological detailsadaptive, parallel group, multicentre, blinded outcome assessment, preplanned sample size re-estimation
- Adaptive
- Parallel group
- Multicentre
- Blinded outcome assessment
- Preplanned sample size re-estimation
Primary result
DAH90 without increased support
Median difference
0
95% CI 0–0
P = 0.75
By group
HFNOT
0
median · IQR 0–79
SOT
0
median · IQR 0–87
HFNOT vs SOT
median difference 0 (95% CI 0–0); P = 0.75
As reported in the abstract
Secondary outcomes
Secondary clinical outcomes, incl. DAH90 without considering additional support
- Similar between groups
Original publication
High-Flow Nasal Oxygen Therapy After Cardiac Surgery: A Randomized Clinical Trial. JAMA Netw Open. Published 1 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →